Joyce A. O’Shaughnessy, MD
Although triple-negative breast cancer (TNBC) remains challenging to treat, promising clinical trial findings are paving the way for new therapies. During a recent OncLive Peer Exchange®
, a panel of breast cancer experts discussed emerging agents, which include an anti–PD-L1 antibody, 2 PARP inhibitors, and a novel antibody–drug conjugate.
Treatment options have been limited, as agents targeting specific molecular markers have often failed to achieve clinically meaningful improvements in outcomes. Subsequently, chemotherapy has remained the standard of care. Now, recent and pending FDA approvals may change that paradigm.
“[This] 40% reduction [in risk of progression or death] was impressive,” McArthur said.
Table. Key Findings in IMpassion130 Trial3
In contrast, the OS benefit in the ITT population did not reach statistical significance, with a median OS of 21.3 months in the atezolizumab group and 17.6 months in the placebo group (HR for death, 0.84; 95% CI, 0.69-1.02; P
= .08). “Because the survival benefit seen in the intention- to-treat population was not significant, the trial investigators were not able to do formal testing; however, the improvement in overall survival in the PD-L1–positive subset was 9.5 months [25.0 months for atezolizumab-treated vs 15.5 months for placebo-treated], which is unprecedented. So this really represents an incredible innovation in an otherwise aggressive and devastating disease,” McArthur said, adding that the trial is “practice-changing.”
... to read the full story